Jie Chai

Jie Chai

Auto-generated profile, based on publicly available information

Jie Chai

Department of Gastrointestinal Surgery, Cancer Hospital Affiliated to Shandong First Medical University, Shandong Cancer Hospital and Institute, Jinan, 250117, People’s Republic of China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
WZWeizhu Zhao
Weizhu Zhao
HYHaiying Yang
Haiying Yang
JCJie Chai
Jie Chai
LXLigang Xing
Ligang Xing
The transcription factor runt-related protein 2 (RUNX2) has an important impact on the transformation of bone marrow mesenchymal stem cells to osteoblasts. Further studies have shown that RUNX2 plays a key role in the invasion and metastasis of cancers. RUNX2 is a “key” molecule in the regulatory network comprised of multiple signaling pathways upstream and its target downstream molecules. Due to the complex regulatory mechanisms of RUNX2, the specific mechanism underlying the occurrence, development and prognosis of malignant tumors has not been fully understood. Currently, RUNX2 as a promising therapeutic target for cancers has become a research hotspot. Herein, we reviewed the current literature on the modulatory functions and mechanisms of RUNX2 in the development of malignant tumors, aiming to explore its potential clinical application in the diagnosis, prognosis and treatment of tumors.

1 November 2016 in Journal of Biomaterials and Tissue Engineering
Verified
Journal Article
Closed access
XZXu Zhou
Xu Zhou
BZBin Zhao
Bin Zhao
JWJinling Wang
Jinling Wang
YZYuanyuan Zhou
Yuanyuan Zhou
JCJie Chai
Jie Chai
YZYilin Zhao
Yilin Zhao
We designed and developed a readily-available vascular graft for in situ tissue engineering using nanoscale decellularized arterial scaffolds modified with heparin hyaluronic acid (HA) hydrogel and sustained release vascular endothelial growth factor (VEGF) gelatin microspheres. Heparin HA hydrogel offered anti-coagulation properties and inhibited platelet aggregation (in vitro and in vivo), while controlled-release VEGF facilitated bone marrow stromal cell proliferation for nearly one month in vitro. Once implanted, the engineered vascular grafts were patent, antithrombotic, assisted the recruitment of endothelial cells in vivo, enhanced endothelium formation and maintained mechanical stability, whereas all the control grafts occluded. Our histological, immunohistochemical and electron microscopic analyses of the engineered vascular grafts demonstrated the existence of endothelial cells, smooth muscle cells and the presence of extracellular components such as collagen and elastin for two months post-implantation. This work demonstrates the feasibility of vascular graft with an anticoagulation activity and can recruit endothelial cells properties for in situ blood vessel regeneration.